Novartis strives to ensure you have everything you need to provide the best care for your patients. Below is a resource designed to support your patients during their journey with PIQRAY.
PIQRAY Patient Brochure
The PIQRAY Patient Brochure is designed to help your patient start their treatment journey. They will learn about why they are prescribed PIQRAY, dosing and administration, and serious and common ARs associated with treatment.
PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components.
Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms, including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia...
PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen...